Clofarabine

證據等級: L5

預測適應症: 10 個

Clofarabine: From Relapsed/Refractory Pediatric ALL to Myeloid Leukemia

One-Sentence Summary

Clofarabine (Clolar) is a second-generation purine nucleoside analog that received accelerated FDA approval in 2004 for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients after at least two prior regimens, though it is not currently marketed in Canada. The TxGNN model predicts it may be effective for Myeloid Leukemia (AML/MDS), with evidence from multiple completed Phase 3 randomized trials and 20 publications firmly supporting this direction. Notably, a 727-patient Phase 3 trial directly comparing clofarabine to standard-of-care chemotherapy in older adults with AML has already been completed, placing this prediction on exceptionally strong clinical footing.

Quick Overview

Item	Content
Original Indication	Not registered in Canada; FDA-approved (2004) for pediatric relapsed/refractory ALL (ages 1–21, ≥2 prior regimens)
Predicted New Indication	Myeloid Leukemia (AML / MDS)
TxGNN Prediction Score	99.88%
Evidence Level	L1 (≥2 completed Phase 3 RCTs identified in the evidence)
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Note on Evidence Level: The automated scoring in this evidence pack assigned L2; however, manual review identified at least two completed Phase 3 randomized controlled trials directly in AML (NCT02085408, n=727; NCT00317642, n=326), qualifying this indication for L1 under the defined criteria.

Why is This Prediction Reasonable?

Clofarabine exerts cytotoxicity through a dual mechanism that is highly relevant to myeloid malignancies. First, it inhibits ribonucleotide reductase (RNR), depleting the intracellular deoxyadenosine triphosphate (dATP) pool and blocking de novo DNA synthesis. Second, its active 5’-triphosphate form competes with natural deoxyribonucleotides for incorporation by DNA polymerase, causing direct chain termination. A third, distinct pathway involves direct disruption of mitochondrial membrane integrity, triggering cytochrome c release and caspase-mediated apoptosis—a route that can bypass Bcl-2 overexpression, one of the most common anti-apoptotic resistance mechanisms in AML blasts.

The connection between clofarabine’s proven activity in ALL and its predicted efficacy in myeloid leukemia is mechanistically grounded: both diseases involve rapidly proliferating hematopoietic progenitor cells with high DNA replication demands and strong dependence on nucleotide salvage pathways. AML blasts and MDS-transforming cells are particularly vulnerable to RNR/DNA polymerase dual inhibition. Critically, clofarabine demonstrates well-characterized synergy with cytarabine—by depleting dCTP pools via RNR inhibition, it competitively enhances the incorporation of cytarabine triphosphate (ara-CTP), amplifying the combined cytotoxic effect. This pharmacodynamic synergy is the biological foundation for the widely studied CLARA (Clofarabine + Cytarabine) and CLAM (Clofarabine + Cytarabine + Mitoxantrone) regimens.

The clinical data go well beyond mechanistic inference. Clofarabine has been evaluated in AML across the full treatment continuum—from induction in newly diagnosed patients (including Phase 3 trials in older adults) to salvage therapy in relapsed/refractory disease, to conditioning regimens for allogeneic stem cell transplantation. The TxGNN model’s high-confidence prediction therefore aligns with a mature and extensively validated clinical direction, rather than representing speculative extrapolation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02085408	Phase 3	Completed	727	Randomized Phase 3 trial comparing clofarabine-based induction and post-remission therapy vs. standard daunorubicin/cytarabine (7+3), followed by decitabine maintenance vs. observation, in newly diagnosed AML in adults ≥60 years
NCT00317642	Phase 3	Completed	326	Randomized, double-blind, controlled Phase 3: clofarabine + cytarabine vs. cytarabine alone in adults ≥55 years with relapsed or refractory AML after 1–2 prior induction regimens
NCT00703820	Phase 3	Completed	324	AML08 multicenter randomized trial: clofarabine + cytarabine vs. conventional anthracycline-based induction in newly diagnosed pediatric AML, with MRD-adapted therapy and NK cell transplantation arm
NCT01101880	Phase 2	Completed	50	CLARA regimen (clofarabine + high-dose cytarabine + G-CSF priming) in adults <65 years with newly diagnosed AML, advanced MDS, or advanced myeloproliferative neoplasm
NCT01295307	Phase 2	Completed	86	Clofarabine salvage monotherapy in relapsed/refractory AML; primary aim to achieve complete remission as a bridge to allogeneic HCT in younger patients
NCT00778375	Phase 2	Completed	122	Clofarabine + low-dose cytarabine induction alternating with decitabine consolidation in frontline AML and high-risk MDS in patients ≥60 years
NCT01457885	Phase 2	Completed	75	Multicenter single-arm study of myeloablative clofarabine + busulfan ×4 (CloBu4) conditioning for allogeneic HCT in non-remission AML; targeted the historically poor-prognosis population
NCT01534702	Phase 1/2	Unknown	60	AMLSG 17-10 trial: three-drug induction (cytarabine + idarubicin + escalating clofarabine) in AML patients at high risk for induction failure; 60 patients enrolled
NCT00838240	Phase 1/2	Unknown	114	EORTC-LG/GIMEMA AML-14A trial: randomized Phase 1/2 studying clofarabine + cytarabine + idarubicin in untreated intermediate/high-risk AML and high-risk MDS in adults aged 18–60 years
NCT00088218	Phase 2	Completed	95	Randomized Phase 2: clofarabine monotherapy vs. clofarabine + low-dose cytarabine in previously untreated AML/high-risk MDS in patients ≥60 years; established activity of the combination

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31246522	2019	Phase 3 RCT Report	J Clin Oncol	AML08 trial report (Rubnitz et al.): clofarabine can replace anthracyclines and etoposide in remission induction for childhood AML without compromising efficacy, meaningfully reducing cumulative cardiotoxicity
32187883	2020	Prospective Phase 2	Cancer Medicine	CLAM regimen (Gill et al.): clofarabine 30 mg/m²/d + cytarabine + mitoxantrone in relapsed/refractory AML (ages 18–65) achieved high response rates and served as an effective bridge to allogeneic HCT
29773602	2018	Phase 1B	Haematologica	van Eijkelenburg et al.: clofarabine replacing fludarabine in combination with high-dose cytarabine and liposomal daunorubicin for pediatric relapsed/refractory AML; Phase 1B dose-finding identifying the recommended Phase 2 dose
31905904	2019	Cohort Analysis	Cancers	Fenwarth et al.: CLARA consolidation regimen improves relapse-free survival specifically in younger AML patients with micro-complex karyotype, identifying a key genomic subgroup most likely to benefit
36336258	2023	Retrospective Cohort	Transplant Cell Ther	Connor et al.: clofarabine + busulfan (Clo/Bu4) myeloablative conditioning for allogeneic HCT in patients with active, chemotherapy-refractory myeloid malignancies; demonstrated antileukemic activity with acceptable toxicity in patients ≤70 years
22957815	2013	Review	Leuk Lymphoma	Ghanem et al.: comprehensive review of clofarabine’s dual RNR/DNA polymerase mechanism and clinical role in AML including first-line and salvage settings; covers combination strategies and resistance patterns
25457773	2015	Review	Crit Rev Oncol Hematol	Fozza et al.: systematic review of clofarabine in adult AML; covers monotherapy, combination regimens in first and second line, and pharmacodynamic synergy with cytarabine
31281098	2019	Clinical Study Report	Lancet Oncol	Stirrups: summary report on clofarabine and cytarabine clinical outcomes in AML; contextualizes findings within the evolving treatment landscape
19852733	2009	Review	Future Oncol	Thomas et al.: early evidence review of clofarabine activity in adult AML; described favorable single-agent activity and emerging combination strategies with cytarabine that would become the CLARA regimen
21182488	2011	Review	Curr Med Chem	Robak et al.: survey of novel and emerging drugs for AML including clofarabine; situates clofarabine among nucleoside analogs, molecular targets, and monoclonal antibodies in the AML therapeutic pipeline

Canada Market Information

Clofarabine (DrugBank ID: DB00631) is not currently marketed in Canada. No Drug Identification Numbers (DINs) are registered with Health Canada, and no product licenses are on file. The drug is commercially available in the United States under the brand name Clolar (Genzyme/Sanofi) with FDA approval for pediatric relapsed/refractory ALL, and has received approval in the European Union and Japan for the same pediatric indication.

Any clinical use of clofarabine for myeloid leukemia in Canada would currently require one of the following pathways:

A Special Access Programme (SAP) request to Health Canada for individual patient access
Enrolment in an authorized clinical trial with a valid CTA (Clinical Trial Application) filed with Health Canada
A formal New Drug Submission (NDS) by a sponsor seeking Canadian market authorization

Cytotoxicity

Clofarabine is a conventional cytotoxic antineoplastic agent (purine nucleoside analog) with well-characterized hematologic toxicity.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Second-generation purine nucleoside analog (deoxyadenosine analog; halogenated purine)
Myelosuppression Risk	High — Profound, dose-dependent myelosuppression is the primary dose-limiting toxicity; severe neutropenia, thrombocytopenia, and anemia are expected and universal in both AML and ALL settings; prolonged aplasia is common and intentional in induction contexts
Emetogenicity Classification	Low to moderate (consistent with other purine nucleoside analogs such as fludarabine and cladribine)
Monitoring Items	Complete blood count with differential (CBC + diff) at baseline and at least twice weekly during induction; serum creatinine and eGFR before each cycle; liver function tests (AST, ALT, total bilirubin) before and during treatment; daily monitoring of blood pressure, weight, and respiratory status for capillary leak syndrome / SIRS signals
Handling Protection	Must be prepared and administered under full cytotoxic drug handling precautions per institutional hazardous drug policies: closed-system drug transfer devices (CSTDs), biological safety cabinet (BSC), PPE including nitrile gloves, gown, and eye protection; cytotoxic waste disposal per regulatory standards

Safety Considerations

Detailed Health Canada product monograph data (key warnings and contraindications) are not available in this evidence pack.

Please refer to the FDA prescribing information (Clolar package insert) and available peer-reviewed safety analyses as an interim reference. Based on the clinical trial literature, clinically important safety signals include: capillary leak syndrome, systemic inflammatory response syndrome (SIRS), severe hepatotoxicity (including veno-occlusive disease in the transplant setting), serious and opportunistic infections during prolonged aplasia, and tumor lysis syndrome. A full drug interaction screen should be performed prior to any clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clofarabine’s activity in myeloid leukemia is backed by an exceptionally mature evidence base—including two large completed Phase 3 randomized controlled trials in AML and a mechanistic rationale that is among the best-characterized in the drug repurposing field. The TxGNN prediction at 99.88% confidence correctly identifies a direction that has already been the subject of over two decades of active clinical investigation. The primary barrier to use in Canada is regulatory (no Health Canada authorization, no DINs), not scientific.

To proceed, the following is needed:

Regulatory pathway clarification: Determine whether to pursue Health Canada SAP access, sponsor a New Drug Submission, or incorporate clofarabine as a comparator/experimental arm within a Canadian clinical trial
Full safety documentation: Retrieve Health Canada-equivalent safety data from the FDA product monograph (Clolar), published toxicity analyses, and the EORTC/GIMEMA safety databases to complete a formal risk assessment
MOA data retrieval: Query the DrugBank API (DB00631) to populate the missing mechanism of action fields required for the complete evidence package
Target population definition: Based on the Phase 3 evidence, prioritize one of: (a) newly diagnosed AML in adults ≥60 years unfit for intensive anthracycline therapy; (b) relapsed/refractory AML as salvage bridge to allogeneic HCT; or (c) pediatric AML as part of a clofarabine-based induction protocol
Canadian landscape assessment: Compare clofarabine’s benefit-risk and cost-effectiveness profile against currently reimbursed AML therapies in Canada (azacitidine, venetoclax + hypomethylating agents, midostaurin for FLT3+ AML) to identify where clofarabine offers distinct clinical value
Pharmacovigilance plan: Given the high myelosuppression burden, design a monitoring and toxicity management protocol appropriate for the Canadian clinical setting before any patient exposure

Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require formal clinical validation before therapeutic application. All predictions are exploratory and must be evaluated through appropriate regulatory and clinical trial processes.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.